Canadian who visited 16 U.S. locations had measles, Seattle health officials say
Article content
Article content
The notice from Public Health — Seattle and King County says the person spent time in King and Snohomish counties between April 30 and May 3 while infectious, and adds that their vaccine status is unknown. (The Seattle metropolitan area overlaps with three counties — King, Snohomish and Pierce.)
Article content
Article content
'In addition to traveling through Seattle-Tacoma International Airport, the person visited multiple public locations in Renton, Bellevue, Seattle, Everett and Woodinville while contagious with measles, but before being diagnosed with measles,' the notice says.
Article content
Article content
The notice then lists 16 locations alongside dates and times, including a winery, two fitness centres and a local hotel as 'locations of potential exposure.'
Article content
'These times include the estimated period when the individual was at the location and two hours after,' the notice says. 'Measles virus can remain in the air for up to two hours after someone infectious with measles leaves the area. Anyone who was at the … locations during the times listed could have been exposed to measles.'
Article content
The health authority says the case is not connected to any previous local measles cases. Public Health — Seattle and King County says it has responded to two other measles cases this year among people who traveled through King County but were not Washington state residents, adding there have been five cases of measles in Washington state residents this year.
Article content
Article content
Measles was declared eliminated in Canada in 1998, and in the United States two years later. However, falling vaccination rates have caused outbreaks to occur in Canada, Mexico, and the U.S., with cross-border transmission as well.
Article content
Article content
Last month, the New York State Department of Health went so far as to issue a travel advisory for those who may be crossing the border, especially anyone travelling to Ontario.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [ 212 Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025. About [ 212 Pb]VMT-α-NET Perspective designed [ 212 Pb]VMT-α-NET to target and deliver 212 Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
CTV News
17 minutes ago
- CTV News
N.S. public health reporting 30 cases of measles in northern part of province
A dose of the measles, mumps, and rubella (MMR) vaccination awaits the next patient during a vaccine clinic in St. Thomas, Ont., on Tuesday, March 4, 2025. THE CANADIAN PRESS/Geoff Robins HALIFAX — Nova Scotia Health says there are now 30 cases of measles in the northern part of the province. The health agency had reported a single case on July 7 in the northern zone, and says it is believed that all 30 infections stem from travel within Canada to regions where measles is known to be circulating. 'Currently, new cases are mainly found in large households and specific, small communities with close contact,' said a Thursday statement from Nova Scotia Health. Health officials said the rise in cases was expected because it's common for secondary infections to appear within seven to 21 days after initial measles cases are identified. Eight of 30 cases in the northern zone have been lab-confirmed and the remaining are considered confirmed based on patients' household exposure and symptoms. Despite the rise in infections, the risk to the general public is still considered low. The provincial health agency is reminding Nova Scotians that the best protection against measles is vaccination, and every person born after 1970 should have two doses of the measles-mumps-rubella vaccine after their first birthday. Nova Scotia's Department of Health says 93.4 per cent of children who turned two years old in 2024 had received one dose of the measles vaccine, and 78.6 per cent were fully vaccinated with two doses. A spokesperson with the department says actual measles vaccination rates in Nova Scotia may be higher 'because of under-reporting.' Scientists, meanwhile, say that a population needs a vaccination rate of 95 per cent — with two doses — to stop measles from spreading. In May, a single case of measles was reported in the Halifax Regional Municipality, but there were no secondary infections identified with the original case, now considered 'resolved.' This report by The Canadian Press was first published July 24, 2025. By Lyndsay Armstrong
CTV News
17 minutes ago
- CTV News
Increase in measles virus detected through wastewater surveillance: WECHU
The Windsor-Essex County Health Unit has sent reminders to school-aged children who are overdue for the measles, mumps, and rubella (MMR) vaccine after an increase in the virus in wastewater surveillance in the region. WECHU says while no direct link has been established between the wastewater signal and school-aged populations, the signal serves as a reminder of the importance of maintaining high community immunization coverage to protect children.' Wastewater surveillance is one of the tools we use to monitor public health trends,' said Dr. Mehdi Aloosh, WECHU medical officer of health. 'Although clinical measles cases remain low, the presence of the virus back in the wastewater suggests that we must remain vigilant.'WECHU is offering catch-up immunization clinics throughout the summer to help families in need of support with immunizations. 'We want to make it as easy as possible for families to access this important vaccine,' said Dr. Aloosh. 'With the school year approaching and the measles virus detected in wastewater, this is a timely opportunity to ensure our community remains protected against measles and other vaccine-preventable diseases.' Residents are encouraged to check their immunization records and contact their healthcare provider or WECHU for help.
